Protalix BioTherapeutics (NYSEMKT:PLX) and collaboration partner Chiesi Global Rare Diseases announce the filing of a U.S. marketing application seeking approval of Fast Track-tagged pegunigalsidase alfa for Fabry disease,
a rare inherited disorder characterized by the buildup of a type of fat
in the body’s cells due to the absence or dysfunction of an essential
enzyme called alpha-galactosidase A.
Pegungalsidase alpha is an enzyme replacement
therapy, specifically, a plant cell culture-expressed and chemically
modified version of recombinant alpha galactosidase A with a half-life
in the body of ~80 hours.
https://seekingalpha.com/news/3578216-u-s-application-filed-for-protalix-bios-pegunigalsidase-alfa-for-fabry
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.